← SynDRA
BOSUTINIB
SynDRA canonical compound SYN0002147 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | CAMK2G |
|---|
| Mechanism of action | Abl kinase inhibitor |
|---|
| Indication | chronic myeloid leukemia (CML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- SRC
- ABL1
- LYN
- HCK
- BCR
- CAMK2G
- CAMK1D
- FRK
- TNK2
- TXK
- MAP4K5
- STK10
Mechanisms of action (all sources)
- SRC inhibitor
- Abl kinase inhibitor
- ABL1 INHIBITOR
- Tyrosine-protein kinase ABL inhibitor
- Tyrosine-protein kinase SRC inhibitor
- HCK INHIBITOR
- Tyrosine-protein kinase HCK inhibitor
- LYN INHIBITOR
- Tyrosine-protein kinase Lyn inhibitor
- BCR INHIBITOR
- CAMK1D INHIBITOR
- CAMK2G INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- YJ005
- ADRA1A
- CHRM2
- ADRA2C
- DLK1
- DRD1
- DRD2
- DRD3
- HTR2A
- HRH3
- HRH2
- AVPR1A
- SLC6A4
- SLC6A3
- GHSR
- ESR1
- ROS1
- ADRA2A
- HTR2C
- PGR
- KCNH2
- TACR1
- PIK3CA
- NEK7
- NEK9
- NPY1R
- PIK3C2G
- PIK3C2B
- OPRD1
- NEK6
- NQO2
- NR3C1
- NTSR1
- OLA1
- OPA1
- PI4KB
- PGRMC1
- NPY2R
- PAK6
- OPRK1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACES
- IFNG
- KCC2G
- KSYK
- M4K5
- NNMT
- NSD2
- NTM1A
- NTMT1
- PNMT
- PPARG
- PRGR
- RARA
- SMAD2
- SMAD3
- TOR1A
- TP53
- KCC1D
- IFNB1
- ANDR
- HSF1
- ATXN2
- CASP3
- CASP7
- CDC25B
- CIB1
- COMT
- CP19A
- CP3A7
- CREB1
- ESRRA
- GAMT
- GLI3
- GNMT
- HLAB
- HNMT
- TSHR
Drug classes
- Bcr-Abl Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- BOSULIF
- BOSUTINIB MONOHYDRATE
- Bosulif
- WAY-173606
- bosulif
- bosutinib monohydrate
- bosutinib hydrate
- SKI 606
- SK-606
- SKI-606
- SKI606
- Bosutinib (USAN)
- PF-5208763
- Xy]-3-quinolinecarbonitrile
- Bosutinib (BCR-ABL inhibitor 3rd gen)
- Bosutinib (SKI-606)
- Bosutinib [USAN]
- SK 606
- BOSUTINIB ISOMER 1
- CHEMBL288441
- CHEBI:39112
- 5018V4AEZ0
- SKI-606)
- Bosutinib (as monohydrate)
- Bosutinib [USAN:INN]
- NCGC00241107-01
- UNII-5018V4AEZ0
- MFCD07367846
- Bosutinib,SKI-606
- BOSUTINIB [INN]
- Bosutinib (SKI606)
- BOSUTINIB [MI]
- BOSUTINIB [VANDF]
- Bosutinib - SKI-606
- BOSUTINIB [MART.]
- EC 700-455-1
- BOSUTINIB [WHO-DD]
- MLS006011212
Reported adverse events
- Abdominal discomfort
- Abdominal pain
- Abdominal pain lower
- Abdominal pain upper
- Acne
- Amylase increased
- Anaphylactic shock
- Angina unstable
- Arthralgia
- Aspartate aminotransferase
- Asthenia
- Back pain
Look up BOSUTINIB in the interactive SynDRA portal →